Korean J Urol.  2007 Jun;48(6):603-607. 10.4111/kju.2007.48.6.603.

The Correlation between Metabolic Syndrome and the Prostate Volume

• Sohn JC
• Chang HS
• Kim CI

• KMID: 1885541
• DOI: http://doi.org/10.4111/kju.2007.48.6.603

Abstract

PURPOSE: This study was conducted to evaluate the relationship between metabolic syndrome and the prostatic volume.
MATERIALS AND METHODS
From January 1997 to December 2006, 555 male out-patients who visited our health care center were investigated and they underwent transrectal ultrasonogram of the prostate. The patients were divided into two groups; group A met the criteria for metabolic syndrome (128 patients) and group B did not meet the criteria (427 patients). The authors compared the age, the prostate-specific antigen (PSA) and the prostate volume between these two groups.
RESULTS
There were no statistically significant differences in age and PSA between the two groups. The prostate volume was significantly larger in group A (39.5+/-17.3cc) than in group B (31.7+/-9.6cc).
CONCLUSIONS
The results of this study proved that metabolic syndrome and the prostate volume are related. Therefore, proper clinical management of metabolic syndrome should accompany the treatment of benign prostatic hyperplasia (BPH).

Keyword

Benign prostatic hyperplasia; Metabolic syndrome

MeSH Terms

Delivery of Health Care
Humans
Male
Outpatients
Prostate*
Prostate-Specific Antigen
Prostatic Hyperplasia
Ultrasonography
Prostate-Specific Antigen

Reference

1. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001. 39:151–158.

2. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004. 172:1390–1393.

3. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep. 2001. 2:297–301.

4. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998. 1:157–162.

5. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori. 2004. 52:291–294.

6. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999. 8:29–36.

7. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001. 39:151–158.

8. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007. 51:199–203.

9. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006. 370:89–93.

10. Kim JH, Shin BS, Kim JS, Hong YS. Voiding dysfunction of men is associated with metabolic syndrome. Korean J Urol. 2006. 47:257–262.

11. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor's clothes fit? Diabetes Care. 2004. 27:1011–1012.

12. Ford ES. Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S. Diabetes Care. 2005. 28:2745–2749.

13. Lim S, Lee HK, Park KS, Cho SI. Changes in the characteristics of metabolic syndrome in Korea over the period 1998-2001 as determined by Korean National Health and Nutrition examination surveys. Diabetes Care. 2005. 28:1810–1812.

14. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, et al. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994. 134:1039–1045.

15. Brochu M, Belanger A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate. 1987. 11:33–40.

16. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature. 1994. 370:341–347.

17. Zaroli A, Mandressi A, Belloni M, Antonelli D, Bernasconi S, Buizza C, et al. Physiopathology of BPH obstruction. Arch Ital Urol Androl. 1995. 67:13–16.

18. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988. 37:1595–1607.

19. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991. 14:173–194.

20. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J. 1994. 15:Suppl C. 78–81.

21. Landsberg L. Diet, obesity an hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptice thermogenesis. Q J Med. 1986. 61:1081–1090.

22. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia. 1989. 32:Suppl. 465A.

23. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990. 17:477–486.

24. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and setum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002. 168:599–604.

25. Eldrup E, Lindholm J, Winkel P. Plasma sex hormones and ischemic heart disease. Clin Biochem. 1987. 20:105–112.

26. Soygur T, Kupeli B, Aydos K, Kupeli S, Arikan N, Muftuoglu YZ, et al. Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol. 1996. 28:55–59.

27. Daniell HW. Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. J Urol. 1993. 149:315–317.

28. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994. 140:989–1002.

29. Kim JH, Shin BS, Hong YS. The relating factors of metabolic syndrome to benign prostatic hyperplasia. Korean J Urol. 2005. 46:1046–1050.